atazanavir sulfate has been researched along with candesartan in 2 studies
Studies (atazanavir sulfate) | Trials (atazanavir sulfate) | Recent Studies (post-2010) (atazanavir sulfate) | Studies (candesartan) | Trials (candesartan) | Recent Studies (post-2010) (candesartan) |
---|---|---|---|---|---|
1,102 | 246 | 590 | 1,929 | 412 | 589 |
Protein | Taxonomy | atazanavir sulfate (IC50) | candesartan (IC50) |
---|---|---|---|
Epidermal growth factor receptor | Homo sapiens (human) | 3.2769 | |
Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 5.9472 | |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 3.0652 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 9 | |
Adenosine receptor A3 | Homo sapiens (human) | 1.2199 | |
Cytochrome P450 2C9 | Homo sapiens (human) | 3 | |
Beta-3 adrenergic receptor | Homo sapiens (human) | 4.3 | |
Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 1.2199 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 3.843 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 3.0652 | |
Thromboxane-A synthase | Homo sapiens (human) | 3.0594 | |
Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0405 | |
Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 1.2199 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (100.00) | 2.80 |
Authors | Studies |
---|---|
Ma, C; Wang, J | 1 |
Huang, YY; Li, Z; Lin, Y; Liu, R; Luo, HB; Wang, X; Zhan, CG | 1 |
2 other study(ies) available for atazanavir sulfate and candesartan
Article | Year |
---|---|
Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors.
Topics: Acetates; Atazanavir Sulfate; Benzimidazoles; Biphenyl Compounds; Chloroquine; COVID-19 Drug Treatment; Cyclopropanes; Dipyridamole; Humans; Oxytetracycline; Pharmaceutical Preparations; Protease Inhibitors; Quinolines; SARS-CoV-2; Sulfides; Tetrazoles | 2021 |
Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors.
Topics: Acetates; Atazanavir Sulfate; Benzimidazoles; Biphenyl Compounds; Chloroquine; COVID-19 Drug Treatment; Cyclopropanes; Dipyridamole; Humans; Oxytetracycline; Protease Inhibitors; Quinolines; Reproducibility of Results; SARS-CoV-2; Sulfides; Tetrazoles | 2021 |